… Before the advent of paclitaxel, the chemotherapeutic agent … nation of doxorubicin with
paclitaxel would result in superior … paclitaxel, and the combination of doxorubicin and paclitaxel (…

… -based paclitaxel. The GeparSepto (GBG 69) trial assessed whether weekly nab-paclitaxel …
paclitaxel, both followed by epirubicin plus cyclophosphamide as neoadjuvant treatment. …

… The addition of bevacizumab to weekly paclitaxel as initial chemotherapy for women with
metastatic or locally recurrent HER2-negative breast cancer results in a statistically significant …

… every 3 weeks as the initial chemotherapeutic regimen for patients with recurrent or metastatic
breast cancer. Although numerous phase II trials with various dose levels of Taxol have …

… obtained with the phase II studies of single-… study in chemotherapy-naive patients, the
phase II studies recruited patients with recurrent or refractory disease after prior chemotherapy …

… Although paclitaxel was given triweekly in phase II trials prior … Patients and Methods: A
phase II trial with response rate as … -line chemotherapy were treated by weekly administration of …

… -paclitaxel arm in this trial than in the 260 mg/m 2 arm in a previous phase III trial of nab-paclitaxel …
) from the randomized phase II trial presented here, a subsequent trial would need to …

… 9.6 months in a phase II study of chemotherapy-naïve patients [… of nab-paclitaxel in metastatic
melanoma, this phase III study … nab-paclitaxel versus dacarbazine in chemotherapy-naïve …

… with doxorubicin-based chemotherapy. Moreover, weekly … phase II clinical trial for metastatic
or locally advanced angiosarcoma. This study establishes the efficacy of weekly paclitaxel …

… phase II data of gemcitabine and paclitaxel (Taxol) (GP), this trial was designed to compare
a short-term (arm A) versus a prolonged (arm B) second-line combination chemotherapy of …